Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05972954Phase 2Completed

OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)

Role: lead

NCT03906799Phase 2Completed

Study on OMT-28 in Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation (AF)

Role: lead

NCT03078738Phase 1Completed

Safety and Pharmacokinetic Study of OMT-28 in Healthy Subjects

Role: lead

All 3 trials loaded